Clinical Trial

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate (pCR) and recurrence-free survival.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-02-24; most recent amendment 2026-07-06.
Status change: Not Yet Recruiting → Recruiting 2025-01-04
Trial Details
NCT Number NCT06288191
Lead Sponsor Melanoma Institute Australia
Collaborators: Bristol-Myers Squibb
Conditions Cutaneous Squamous Cell Carcinoma
Enrollment 20 participants
Start Date 2024-06-21
Primary Completion 2026-09 (estimated)
Study Completion 2036-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-08